

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7507318

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RUNSHENG LI	07/13/2022
WENTAO HUANG	07/13/2022
RECEIVING PARTY DATA	
Name:	LANOVA MEDICINES DEVELOPMENT CO., LTD.
Street Address:	NO. 177, GROUP 6, RENNAN VILLAGE, KANGQIAO TOWN
Internal Address:	PUDONG NEW DISTRICT
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201315
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17685029
CORRESPONDENCE DATA	
Fax Number:	(650)815-2601
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508152600
Email:	ccarter@sheppardmullin.com
Correspondent Name:	SHEPPARD MULLIN RICHTER & HAMPTON LLP
Address Line 1:	1540 EL CAMINO REAL, SUITE 120
Address Line 2:	ALEX Y. NIE
Address Line 4:	MENLO PARK, CALIFORNIA 94025
ATTORNEY DOCKET NUMBER:	70LG-325887-US
NAME OF SUBMITTER:	ALEX Y. NIE
SIGNATURE:	/Alex Y. Nie/
DATE SIGNED:	08/26/2022
Total Attachments: 2	
source=Assignment-Worldwide (ANTI-GPRC5D)_signed#page1.tif	
source=Assignment-Worldwide (ANTI-GPRC5D)_signed#page2.tif	

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

**LaNova Medicines Development Co., Ltd.
No. 177, Group 6, Rennan Village, Kangqiao Town
Pudong New District, Shanghai, China 201315**

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

ANTI-GPRC5D MONOCLONAL ANTIBODIES AND USES THEREOF

as set forth in United States Patent Application

check one ☐ executed concurrently herewith,
 ☐ executed on _____,
 ☒ Serial No.: 17/685,029 Filed March 2, 2022

as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **Sheppard Mullin Richter & Hampton LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **Sheppard Mullin Richter & Hampton LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

ASSIGNOR/INVENTOR(S):

NAME: Runsheng Li


SIGNATURE: Runsheng Li DATE: July 13, 2022

NAME: Wentao Huang

SIGNATURE: Wentao Huang DATE: 07/13/2022

ASSIGNEE:

LaNova Medicines Development Co., Ltd.

Signature: 
Name: Ying Qin Yang
Title: Chief Executive Officer
Date: _____